These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7823874)

  • 21. 1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression.
    Clark CS; Konyer JE; Meckling KA
    Exp Cell Res; 2004 Mar; 294(1):301-11. PubMed ID: 14980523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein kinase C-alpha in prostate cancer.
    Lahn M; Sundell K; Gleave M; Ladan F; Su C; Li S; Ma D; Paterson BM; Bumol TF
    BJU Int; 2004 May; 93(7):1076-81. PubMed ID: 15142167
    [No Abstract]   [Full Text] [Related]  

  • 23. The expression of desmoglein isoforms in cultured human keratinocytes is regulated by calcium, serum, and protein kinase C.
    Denning MF; Guy SG; Ellerbroek SM; Norvell SM; Kowalczyk AP; Green KJ
    Exp Cell Res; 1998 Feb; 239(1):50-9. PubMed ID: 9511724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
    Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signal transduction inhibitors as novel anticancer drugs: where are we?
    Workman P
    Ann Oncol; 1992 Jul; 3(7):527-31. PubMed ID: 1498072
    [No Abstract]   [Full Text] [Related]  

  • 26. Potential for protein kinase C inhibitors in cancer therapy.
    Philip PA; Harris AL
    Cancer Treat Res; 1995; 78():3-27. PubMed ID: 8595146
    [No Abstract]   [Full Text] [Related]  

  • 27. Chemistry and clinical biology of the bryostatins.
    Mutter R; Wills M
    Bioorg Med Chem; 2000 Aug; 8(8):1841-60. PubMed ID: 11003129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifunctional modulators of drug resistance.
    Murren JR; Rappa G; Cheng YC
    Cancer Treat Res; 1996; 87():381-408. PubMed ID: 8886462
    [No Abstract]   [Full Text] [Related]  

  • 29. The bryostatins.
    Pettit GR
    Fortschr Chem Org Naturst; 1991; 57():153-195. PubMed ID: 1937312
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis and in vitro cancer cell growth inhibitory activity of monocyclic model compounds containing spongistatin triene side-chains.
    Smith AB; Lin Q; Pettit GR; Chapuis JC; Schmidt JM
    Bioorg Med Chem Lett; 1998 Mar; 8(6):567-8. PubMed ID: 9871561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological response modifiers and chemotherapeutic agents that alter interleukin 2 activities.
    West WL; Rhoads AR; Akogyeram CO
    Immunol Ser; 1994; 61():207-26. PubMed ID: 8011745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth factors in leukemia: how it all begins.
    Ragab A
    J Pediatr Oncol Nurs; 1990 Apr; 7(2):56. PubMed ID: 2363875
    [No Abstract]   [Full Text] [Related]  

  • 33. Protein kinase C in cell growth and differentiation.
    Kuo JF; Shoji M; Kiss Z; Girard PR; Deli E; Oishi K; Vogler WR
    Adv Exp Med Biol; 1989; 255():8-20. PubMed ID: 2618875
    [No Abstract]   [Full Text] [Related]  

  • 34. Growth-control mechanisms.
    Lancet; 1967 Oct; 2(7522):927-8. PubMed ID: 4167862
    [No Abstract]   [Full Text] [Related]  

  • 35. Macrosphelides C and D, novel inhibitors of cell adhesion.
    Takamatsu S; Hiraoka H; Kim YP; Hayashi M; Natori M; Komiyama K; Omura S
    J Antibiot (Tokyo); 1997 Oct; 50(10):878-80. PubMed ID: 9402995
    [No Abstract]   [Full Text] [Related]  

  • 36. Screening of immunological properties of vermiculine in selected model situations.
    Rovenský J; Buc M; Blazícková S; Ferencík M; Rauová L; Fuska J; Stancíková M
    Ann N Y Acad Sci; 1997 Apr; 815():369-71. PubMed ID: 9186682
    [No Abstract]   [Full Text] [Related]  

  • 37. [Protein kinase C. Key enzyme for immune reactions and cell growth].
    Hellwiq B
    Med Monatsschr Pharm; 1994 Nov; 17(11):326-8. PubMed ID: 7823874
    [No Abstract]   [Full Text] [Related]  

  • 38. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
    Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
    Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo.
    La Porta CA; Di Dio A; Porro D; Comolli R
    Melanoma Res; 2000 Apr; 10(2):93-102. PubMed ID: 10803709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein kinase C in signal transduction and carcinogenesis.
    Blumberg PM; Acs G; Areces LB; Kazanietz MG; Lewin NE; Szallasi Z
    Prog Clin Biol Res; 1994; 387():3-19. PubMed ID: 7972255
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.